Last reviewed · How we verify
NT-proBNP Measurements to Rule-out Heart Failure Among Patients With Atrial Fibrillation: A Prospective Clinical Study (ProAF)
This study aims to investigate N-terminal pro brain natriuretic peptide (NT-proBNP) as a biomarker to rule out heart failure in patients with atrial fibrillation. Atrial fibrillation and heart failure often co-exist. Heart failure is important to identify, as part of the medical treatment for patients with atrial fibrillation can be fatal if the patient has concomitant heart failure. Performing an echocardiography is considered "gold standard" for assessing cardiac function but echocardiography may not always be readily available during acute hospitalization. The cardiac biomarker NT-proBNP can be used to rule out acute heart failure in patients with sinus rhythm. However, atrial fibrillation affects levels of NT-proBNP in the blood and it is therefore unknown, how the biomarker performs in atrial fibrillation patients.
Details
| Lead sponsor | University of Aarhus |
|---|---|
| Status | UNKNOWN |
| Enrolment | 403 |
| Start date | Mon Nov 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Mar 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Atrial Fibrillation
- Heart Failure
Countries
Denmark